On February 26, the first injection ceremony of the world's first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine was held in Hainan. On the same day, Ms. Liao, a citizen of Haikou, held her two-month-old baby and received a double-carrier 13-valent pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as the "13-valent pneumonia vaccine") at the Hainan Provincial Women's and Children's Medical Center, which will be used in Hainan and will bring more effective, safer and more economical and diversified choices to the public.
Ms. Liao told reporters that the price of this 13-valent pneumonia vaccine is relatively grounded, within the economic affordability range, before Dabao did not timely vaccinate the 13-valent pneumonia vaccine and was infected with pneumonia, this time with the second treasure to vaccinate, the heart will be relieved.
It is understood that the dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine is the second approved vaccine in China and the third approved vaccine for 13-valent pneumonia in the world. The dual-carrier 13-valent pneumonia vaccine has a good effect on infants and children aged 6 weeks to 5 years (before the 6th birthday) and greatly relaxes the time limit for vaccination.
Pneumonia is a common disease in children, high incidence, every autumn and winter, the hospital pediatric outpatient clinics, inpatient departments are often overcrowded. The common causes of pneumonia are bacterial infections and viral infections, of which Streptococcus pneumoniae is the main pathogen causing bacterial pneumonia, it colonizes the nasopharynx of people, when immunity declines or infection with influenza, pneumococcus will take the opportunity to "mess up", infecting the lungs will cause pneumonia, fever, cough and other symptoms, infection of other parts will cause meningitis, sinusitis, otitis media, bacteremia and a series of diseases, serious will also cause acute infectious shock and other serious diseases, and even life-threatening.
In recent years, the drug resistance of pneumococcal bacteria has been increasing, and in 2017, pneumococcus was included in the list of "deadly drug-resistant bacteria that seriously threaten human health" by the World Health Organization. "Pneumococcal pneumonia is an important disease that seriously endangers the health of children and is one of the leading causes of death in children under 5 years of age." Fu Zhenwang, director of the Immunization Program Office of the Hainan Provincial Center for Disease Control and Prevention, said that vaccinating children against pneumonia is the fundamental way to solve the problem of antibiotic resistance, and it is the best protection for children from abuse. In winter, the risk of cross-infection between children increases, so vaccination against pneumonia is a cost-effective means of controlling pneumonia disease. Children under 5 years of age, whose immune function is not yet fully developed, are at constant risk of pneumococcal invasion. Once infected with pneumococcal disease, it is very likely to cause serious sequelae such as mental retardation and paralysis.
In the past decade, the 13-valent pneumonia vaccine in the mainland has been in the form of foreign vaccine supply, and in 2021, the mainland began to have its own self-developed domestic pneumonia vaccine.
Huang Min, deputy director of the Haikou Institute of Skin and Venereal Diseases and Psychiatric Prevention and Control, said that there are currently 3 13-valent pneumonia vaccines in China, and the entry and use of this dual-carrier 13-valent pneumonia vaccine will provide parents with more choices, further reduce the economic burden of parents to vaccinate their children at their own expense, and is of great significance for protecting children's health and promoting the further improvement of vaccine immunization prevention.
It is understood that this Uyghur Fippel 13-valent pneumonia vaccine uses two carrier proteins (tetanus toxoid / diphtheria toxoid) combined with pneumococcal capsular polysaccharides, which is the world's first double-carrier 13-valent pneumococcal polysaccharide conjugate vaccine.
Zheng Jingshan, director of biomedicine at Kangtai, introduced that the use of dual-carrier pneumonia vaccines can avoid the competition of single carrier proteins for helper T cells and have an inhibitory effect on polysaccharide immune responses. The phase III clinical trial data of the vaccine show that the antibody positivity rate and the geometric average titer of antibodies for 13 serotypes of pneumococcal bacteria are not inferior to similar imported products. At the same time, the safety of the vaccine is good, the adverse reactions are mild, and in clinical trials, the incidence of adverse reactions is lower than that of the control group products.